PALI-2108
Small molecule
Evidence outlook
Ulcerative Colitis: mid-stage studies underway, no completed readout
In Ulcerative Colitis, Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. Studies in other indications have read out; see the trials and Regulatory events below.
Also in development:Crohn's Disease · Phase 1
Company guidance: data expected fourth quarter of 2027 (NCT07845487; Palisade Bio, 10 Nov 2026). “Primary efficacy results for ASCENTRA-UC are expected in the fourth quarter of 2027.” Source ↗
Company guidance: topline data expected Q4 2027 (NCT07845487; Palisade Bio, 10 Nov 2026). “First Patient Dosed in Global Phase 2b ASCENTRA-UC Trial; Topline Results Expected in Q4 2027” Source ↗
Company guidance: topline data expected first quarter of 2028 (Palisade Bio, 10 Nov 2026). “Further, beyond the readout expected in the first quarter of 2028, we will require additional financing to continue at our expected level of operations, which would include a potential Phase 3 clinical trial and possible commercialization of PALI-2108 for the treatment of UC and CD.” Source ↗
The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT06663605 NCT06663605 · Ulcerative Colitis (UC), Healthy Volunteer Most of this study randomized healthy volunteers to PALI-2108 or matching placebo under double-blind conditions, though the ulcerative colitis patient cohort was open-label. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Its registered primary outcome on ClinicalTrials.gov is "Incidence of Treatment-Emergent Adverse Events (TEAE) or abnormal clinical laboratory measure, electrocardiogram (ECG), or vital sign. [ Safety and Tolerability ]". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak. Registry: NCT06663605 | 1 | Incidence of Treatment-Emergent Adverse Events (TEAE) or abnormal clinical laboratory measure, electrocardiogram (ECG), or vital sign. [ Safety and Tolerability ] (SAD and FE Phase: [ Day 1 to Day 7 ], MAD and UC Phase: [ Days 1 to Day 28 ]) 2025-07-07 | Phase 1a: the study met its primary endpoints of safety, tolerability and pharmacokinetics, with no serious adverse events and no treatment-emergent adverse events related to laboratory values or EKGs across the single and multiple ascending dose cohorts. In the single-dose study (15 to 450 mg) only mild, reversible treatment-emergent adverse events occurred, limited to the 450 mg dose. Multiple-dose cohorts (15, 30 and 50 mg twice daily over 7 days, and 30 mg titrated over 7 days) showed mostly minor events, with one moderate event at 50 mg twice daily leading to withdrawal. | Weak signal | link ↗ |
View 1 more trial
ASCENTRA-UC NCT07845487 · Ulcerative Colitis Registry: NCT07845487 | 2 | Proportion of participants with clinical remission using the 3-component modified Mayo Score (mMS) at Week 12. 2027-10 | In progress: results expected 1 Oct 2027 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (1)
What this study did
Phase 1 (2)
What this study did
What this study did
Competitive landscape
Other PDE4 drugs
apremilast, crisaborole, difamilast, Roflumilast (Daliresp), Roflumilast (Zoryve foam) and 5 more. Compare all 11 PDE4 drugs
This mechanism is crowded: 11 other tracked programmes target it, 8 of them ahead of this one.
This drug's own stage for Ulcerative Colitis: Phase 2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| PALI-2108: this drug | Phase 2 | Small molecule | PDE4 | Weak signal | Featured results are safety only in this race | |
| Adalimumab (Humira) | Approved | Monoclonal antibody | TNF-alpha | Partial signal | NCT00408629: Proportion of Participants Who Achieved Clinical Remission Per Mayo Score at Week 8 (Week 8): Adalimumab 160/80/40 16.5% vs Placebo 9.3%; p=0.019 (Adalimumab 160/80/40 vs Placebo) NCT02065557: Induction (Week 8, ITT-E, Main Study): I-SD 43.3% vs external placebo 19.83% (p=0.382, NS); I-HD 59.6% vs external placebo (p<0.001); combined I-SD+I-HD 53.2% (p<0.001). Maintenance (Week 52, mITT-E): M-PL 33.3% (n=12, descriptive only); M-SD 29.0% vs external placebo 18.37% (p=0.382, NS); M-HD 45.2% (p<0.001); combined M-SD+M-HD 37.1% (p<0.001). | |
| Adalimumab-Aacf (Idacio) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Aaty (Yuflyma) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Adaz (Hyrimoz) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Adbm (Cyltezo) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Afzb (Abrilada) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Aqvh (Yusimry) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Atto (Amjevita) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Bwwd (Hadlima) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Fkjp (Hulio) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Ryvk (Simlandi) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Apremilast (Otezla) | Approved(overall) | Small molecule | PDE4 | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Balsalazide Disodium (Colazal) | ApprovedUS marketing discontinued | Small molecule | Aminosalicylate | not yet graded | No reviewed efficacy summary in this indication | |
| Budesonide (Uceris Rectal Foam) | Approved | Small molecule | Glucocorticoid receptor | Reliable signal | No reviewed efficacy summary in this indication | |
| Budesonide MMX (Uceris) | Approved | Small molecule | Glucocorticoid receptor | Partial signal | NCT01532648: Registered primary, clinical remission at day 56 (UCDAI rectal bleeding and stool frequency subscores of 0), budesonide MMX 9 mg vs placebo added to oral mesalamine: 56/230 vs 52/228 (CT.gov); similar in both groups, p=0.70 (Rubin 2017). Combined clinical and endoscopic remission at week 8: 13.0% vs 7.5%, p=0.049. missed | |
| Crisaborole (Eucrisa) | Approved(overall) | Small molecule | PDE4 | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Dexamethasone | Approved | Small molecule | Glucocorticoid receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Difamilast (Moizerto / Adquey) | Approved(overall) | Small molecule | PDE4 | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Etrasimod (Velsipity) | Approved | Small molecule | S1P receptor | Reliable signal | NCT03945188: Percentage of Participants Achieving Clinical Remission at Week 12 (At Week 12): Etrasimod 2 mg 27.0% vs Placebo 7.4%; p=<0.001 (Etrasimod 2 mg vs Placebo) NCT03996369: Percentage of Participants Achieving Clinical Remission (Week 12): Etrasimod 2 mg 24.8% vs Placebo 15.2%; p==0.026 (Etrasimod 2 mg vs Placebo) | |
| Golimumab (Simponi) | Approved | Monoclonal antibody | TNF-alpha | Reliable signal | NCT01863771: Number of Participants Who Achieved Clinical Response Through Maintenance-Week 54 Measured Using the Mayo Score (Up to Week 54): Placebo 6/31 (19.4%) (95% CI 5.4-33.3) vs Golimumab 18/32 (56.3%) (95% CI 39.1-73.4) NCT00488631: Number of Participants in Clinical Response Through Week 54 (Induction Baseline, Week 0 through Week 54): Golimumab Induction Responders (GLM-I-Rsp)-Placebo Maintenance 48/154 (31.2%) vs GLM-I-Rsp-Golimumab 50 mg Maintenance 71/151 (47.0%) vs GLM-I-Rsp-Golimumab 100 mg Maintenance 75/151 (49.7%); p=0.010 (Golimumab Induction Responders (GLM-I-Rsp)-Placebo Maintenance vs GLM-I-Rsp-Golimumab 50 mg Maintenance), p=<0.001 (Golimumab Induction Responders (GLM-I-Rsp)-Placebo Maintenance vs GLM-I-Rsp-Golimumab 100 mg Maintenance) | |
| Guselkumab (Tremfya) | Approved | Monoclonal antibody | IL-23 p19 | Reliable signal | NCT05528510: Percentage of Participants in Clinical Remission at Week 12 (Week 12): Placebo 6.5 Percentage of participants (95% CI 2.4 to 10.6) | Combined Guselkumab 400 mg 27.6 Percentage of participants (95% CI 22.4 to 32.8) QUASAR/GALAXI: superior to ustekinumab on pooled endoscopic endpoints | |
| Hydrocortisone (Cortenema) | Approved | Small molecule | Glucocorticoid receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Hydrocortisone Acetate (Cortifoam) | Approved | Small molecule | Glucocorticoid receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Infliximab (Remicade) | Approved | Monoclonal antibody | TNF-alpha | Weak signal | NCT01585155: Percent of Patients Who Achieved CAI Remission (Weeks 2, 6, 8, 10, 14, 18, 22, 26, 30, and the last time point during the period from administration of the study drug to Week 30): TA-650 — Weeks 2: 60%; Weeks 6: 80%; Weeks 8: 80%; Weeks 10: 77.8%; Weeks 14: 87.5%; Weeks 18: 87.5%; Weeks 22: 64.3%; Weeks 26: 85.7%; Weeks 30: 64.3%; The last time point: 42.9% NCT00336492: The Number of Participants With Clinical Response at Week 8 (Week 8): Infliximab 5 mg/kg 44/60 (73.3%) | |
| Infliximab-Abda (Renflexis) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Infliximab-Axxq (Avsola) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Infliximab-Dyyb (Inflectra) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Infliximab-Dyyb (Zymfentra) | Approved | Monoclonal antibody | TNF-alpha | Reliable signal | No reviewed efficacy summary in this indication | |
| Infliximab-Qbtx (Ixifi) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Mesalamine (Apriso) | Approved | Small molecule | Aminosalicylate | not yet graded | No reviewed efficacy summary in this indication | |
| Mesalamine (Canasa) | Approved | Small molecule | Aminosalicylate | not yet graded | No reviewed efficacy summary in this indication | |
| Mesalamine (Lialda) | Approved | Small molecule | Aminosalicylate | Reliable signal | NCT00151892: Endoscopic Remission of Ulcerative Colitis (UC) at 6 Months (6 Months): SPD476 83.7 percent of participants | Asacol 81.5 percent of participants | |
| Mesalamine (Pentasa) | Approved | Small molecule | Aminosalicylate | not yet graded | No reviewed efficacy summary in this indication | |
| Mesalamine (Rowasa) | Approved | Small molecule | Aminosalicylate | not yet graded | No reviewed efficacy summary in this indication | |
| Methylprednisolone | Approved | Small molecule | Glucocorticoid receptor agonist | not yet graded | No reviewed efficacy summary in this indication | |
| Mirikizumab (Omvoh) | Approved | Monoclonal antibody | IL-23 p19 | Reliable signal | NCT03524092: Percentage of Participants in Clinical Remission at Week 40 (Mirikizumab Induction Responders) (Week 40): Maintenance Period: Miri IR - 200 mg Miri SC 49.9% (95% CI 44.7 to 55) vs Maintenance Period: Miri IR - PBO SC 25.1% (95% CI 18.8 to 31.5) NCT03518086: Percentage of Participants With Clinical Remission at Week 12 (Week 12): Placebo IV Q4W 13.3% (95% CI 6.9-19.6) vs 300 mg Mirikizumab IV Q4W 24.2% (95% CI 19.5-28.9); p=0.00006 (Placebo IV Q4W vs 300 mg Mirikizumab IV Q4W) | |
| Olsalazine (Dipentum) | Approved | Small molecule | Aminosalicylate | not yet graded | No reviewed efficacy summary in this indication | |
| Ozanimod (Zeposia) | Approved | Small molecule | S1P receptor | Reliable signal | NCT02435992: Percentage of Participants in Clinical Remission at 10 Weeks (At 10 Weeks): RPC1063 Cohort 1(Induction Period) 18.4% vs Placebo Cohort 1 (Induction Period) 6.0% vs RPC1063 Cohort 2 (Induction Period) 21.0%; p=0.0001 (RPC1063 Cohort 1(Induction Period) vs Placebo Cohort 1 (Induction Period)) NCT03915769: Clinical response at week 12: 52.9% (0.46 mg) and 61.5% (0.92 mg) vs 32.3% placebo. | |
| Risankizumab (Skyrizi) | Approved | Monoclonal antibody | IL-23 p19 | Reliable signal | INSPIRE/COMMAND: clinical remission + endoscopic improvement met NCT03398148: Sub-Study 1: Percentage of Participants Achieving Clinical Remission Per Adapted Mayo Score (Week 12): Substudy 1, Induction Period 1: Double-blind Placebo IV 1/60 (1.7%) vs Substudy 1, Induction Period 1: Double-blind Risankizumab 600mg IV 7/61 (11.5%) vs Substudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IV 6/61 (9.8%) vs Substudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IV 6/58 (10.3%) vs Substudy 1, Induction Period 1: Open-label Risankizumab 1800mg IV 42/340 (12.4%); p=0.0324 (Substudy 1, Induction Period 1: Double-blind Placebo IV vs Substudy 1, Induction Period 1: Double-blind Risankizumab 600mg IV), p=0.0460 (Substudy 1, Induction Period 1: Double-blind Placebo IV vs Substudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IV), p=0.0397 (Substudy 1, Induction Period 1: Double-blind Placebo IV vs Substudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IV) | |
| Roflumilast (Daliresp) | Approved(overall) | Small molecule | PDE4 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Roflumilast (Zoryve Foam) | Approved(overall) | Small molecule | PDE4 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Roflumilast (Zoryve) | Approved(overall) | Small molecule | PDE4 | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Sulfasalazine | Approved | Small molecule | Aminosalicylate | not yet graded | No reviewed efficacy summary in this indication | |
| Tofacitinib (Xeljanz) | Approved | Small molecule | JAK, JAK1/JAK3 | Reliable signal | NCT01458574: Percentage of Participants In Remission at Week 52 (Week 52): Tofacitinib 5 mg BID 34.3% vs Tofacitinib 10 mg BID 40.6% vs Placebo 11.1%; p=<0.0001 (Tofacitinib 5 mg BID vs Placebo), p=<0.0001 (Tofacitinib 10 mg BID vs Placebo) NCT01458951: Percentage of Participants With Remission at Week 8 (Week 8): Tofacitinib 10 mg BID 16.6% vs Placebo BID 3.6%; p=0.0005 (Tofacitinib 10 mg BID vs Placebo BID) | |
| Upadacitinib (Rinvoq) | Approved | Small molecule | JAK, JAK1 | Reliable signal | NCT03653026: Percentage of Participants Who Achieved Clinical Remission Per Adapted Mayo Score at Week 8 (Week 8): Upadacitinib 45 mg 33.5% (95% CI 28.5-38.5) vs Placebo 4.1% (95% CI 1.1-7.1); p=<0.001 (Upadacitinib 45 mg vs Placebo) NCT02819635: Substudy 1: Percentage Of Participants Who Achieved Clinical Remission Per Adapted Mayo Score at Week 8 (At Week 8): SS1: Placebo 0% vs SS1: Upadacitinib 7.5 mg 8.5% vs SS1: Upadacitinib 15 mg 14.3% vs SS1: Upadacitinib 30 mg 13.5% vs SS1: Upadacitinib 45 mg 21.4%; p=0.049 (SS1: Placebo vs SS1: Upadacitinib 7.5 mg), p=0.010 (SS1: Placebo vs SS1: Upadacitinib 15 mg), p=0.007 (SS1: Placebo vs SS1: Upadacitinib 30 mg), p=<0.001 (SS1: Placebo vs SS1: Upadacitinib 45 mg) | |
| Ustekinumab (Stelara) | Approved | Monoclonal antibody | IL-12 p40 | Reliable signal | NCT02407236: Induction Study - Number of Participants With Clinical Remission at Week 8 (As Per Global Definition) (Week 8): Induction Study (IS): Placebo Intravenous (IV) 17/319 (5.3%) vs IS: Ustekinumab 130 Milligram (mg) IV 50/320 (15.6%) vs IS: Ustekinumab Approximately 6 mg/kg IV 50/322 (15.5%); p=< 0.001 (Induction Study (IS): Placebo Intravenous (IV) vs IS: Ustekinumab 130 Milligram (mg) IV), p=< 0.001 (Induction Study (IS): Placebo Intravenous (IV) vs IS: Ustekinumab Approximately 6 mg/kg IV) NCT04630028: Week 8 clinical remission 25% (27/107) after IV induction; the study's primary endpoint is week 52 remission in week 8 responders. | |
| Ustekinumab-Aauz (Otulfi) | Approved | — | IL-12 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Ustekinumab-Aekn (Selarsdi) | Approved | Monoclonal antibody | IL-12 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Ustekinumab-Auub (Wezlana) | Approved | Monoclonal antibody | IL-12 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Ustekinumab-Hmny (Starjemza) | Approved | Monoclonal antibody | IL-12 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Ustekinumab-Srlf (Imuldosa) | Approved | Monoclonal antibody | IL-12 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Ustekinumab-Stba (Steqeyma) | Approved | Monoclonal antibody | IL-12 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Ustekinumab-Ttwe (Pyzchiva) | Approved | Monoclonal antibody | IL-12 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Vedolizumab (Entyvio) | Approved | Monoclonal antibody | α4β7 integrin | Reliable signal | NCT02497469: Percentage of Participants Who Achieved Clinical Remission (Week 52): Adalimumab SC, 160/80/40 mg 22.5% (95% CI 18.5-27.0) vs Vedolizumab IV 300 mg 31.3% (95% CI 26.7-36.2); p=0.0061 (Adalimumab SC, 160/80/40 mg vs Vedolizumab IV 300 mg) NCT02611830: Percentage of Participants Achieving Clinical Remission at Week 52 (Week 52): Maintenance Phase: Induction IV + Placebo 14.3% (95% CI 6.4-26.2) vs Maintenance Phase: Induction IV + Vedolizumab 108 mg SC 46.2% (95% CI 36.5-56.2) vs Maintenance Phase: Induction IV + Vedolizumab 300 mg IV 42.6% (95% CI 29.2-56.8); p=<0.001 (Maintenance Phase: Induction IV + Placebo vs Maintenance Phase: Induction IV + Vedolizumab 108 mg SC) | |
| Mesalamine (Asacol HD) | US approval withdrawn | Small molecule | Aminosalicylate | Partial signal | No reviewed efficacy summary in this indication | |
| Afimkibart | Phase 3 | Monoclonal antibody | TL1A | Partial signal | NCT04090411: Induction Period: Percentage of Participants Who Achieved Clinical Remission at Week 14 (At Week 14): Induction Period: Placebo 11.6% (95% CI 5.77-22.88) vs Induction Period: PF-06480605 50 mg 25.5% (95% CI 15.44-37.19) vs Induction Period: PF-06480605 150 mg 23.3% (95% CI 14.98-33.98) vs Induction Period: PF-06480605 450 mg 23.9% (95% CI 16.58-32.06); p=0.0545 (Induction Period: Placebo vs Induction Period: PF-06480605 50 mg), p=0.0823 (Induction Period: Placebo vs Induction Period: PF-06480605 150 mg), p=0.0642 (Induction Period: Placebo vs Induction Period: PF-06480605 450 mg) missed | |
| Duvakitug | Phase 3 | Monoclonal antibody | TL1A | Partial signal | NCT05499130: UC cohort, clinical remission at week 14: 36% (450 mg) / 48% (900 mg) vs 20% placebo, placebo-adjusted 16% (p=.050) / 27% (p=.003). CD cohort, endoscopic response: 26.1% (low dose) / 47.8% (high dose) vs 13.0% placebo. P-values are one-sided at a 0.10 significance level. | |
| Icotrokinra (Icotyde) | Phase 3 | Peptide | IL-23 receptor | Reliable signal | NCT06049017: Primary endpoint clinical response at Week 12: 63.5% with the highest icotrokinra dose vs 27% with placebo (p<0.001) | |
| JNJ-78934804 | Phase 3 | Combination | IL-23 p19, TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Mufemilast | Phase 3 | Small molecule | PDE4 | not yet graded | No reviewed efficacy summary in this indication | |
| Obefazimod | Phase 3 | Small molecule | miR-124 | Reliable signal | NCT05535946: ABTECT maintenance, clinical remission at Week 44: placebo 10.4% (20), 25 mg 50.8% (98; placebo-adjusted +39.3%), 50 mg 51.3% (100; placebo-adjusted +40.3%), p<0.0001 NCT05507203: ABTECT-1 (NCT05507203), clinical remission at Week 8: placebo 2.5% (4/158), 25 mg 23.8% (38/160, p<0.0001), 50 mg 21.7% (69/318, p<0.0001; placebo-adjusted +19.3%) | |
| Ponesimod | Phase 3 | Small molecule | S1P receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Prifemilast (HPP737) | Phase 3(overall) | Small molecule | PDE4 | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Tulisokibart | Phase 3 | Monoclonal antibody | TL1A | Reliable signal | NCT06052059: ATLAS-UC Study 2 (NCT06052059): tulisokibart met its primary endpoint of clinical remission (Modified Mayo Score) at week 12, plus key secondary endpoints. NCT04996797: Remission 26% vs 1% placebo; +25pp (95% CI 14–37) | |
| AC-101 | Phase 2 | Small molecule | RIPK2 | not yet graded | No reviewed efficacy summary in this indication | |
| ALTB-268 | Phase 2 | Monoclonal antibody | PSGL-1 | Weak signal | No reviewed efficacy summary in this indication | |
| ALTO-101 | Phase 2(overall) | Small molecule | PDE4 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Amiselimod | Phase 2 | Small molecule | S1P receptor | Reliable signal | NCT04857112: Change from baseline in modified Mayo Score at Day 85: amiselimod -2.3 vs placebo -1.6 (p=0.002) | |
| ATH-063 | Phase 2 | Small molecule | G9A (EHMT2) | Weak signal | Featured results are safety only in this race | |
| Morcamilast | Phase 2(overall) | Small molecule | PDE4 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| MT-201 | Phase 2 | Biologic (subtype unspecified) | — | not yet graded | No reviewed efficacy summary in this indication | |
| MT-501 | Phase 2 | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| Omilancor | Phase 2 | Small molecule | LANCL2 | Partial signal | NCT03861143: Clinical Remission (Week 12): BT-11 Low-dose (440 mg) 30.3% | BT-11 High-dose (880 mg) 31.8% vs Placebo 22.7% | |
| Zotemtegrast | Phase 2 | Small molecule | α4β7 integrin | Weak signal | NCT05611671: Percentage of Participants in Clinical Remission as Determined Using the Modified Mayo Clinic Score (mMCS) (Week 12): MORF-057 200 mg BID 31.9% | MORF-057 100 mg BID 23.9% | MORF-057 100 mg QD-M 17.1% vs Placebo 24.3% missed NCT05291689: Main Cohort: Change From Baseline to Week 12 in the Robarts Histopathology Index (RHI) Score (From baseline to 12 weeks): MORF-057 (Main Cohort) -6.4 score on a scale (Standard Deviation 11.18) | |
| ICG318 | Phase 1/2 | Cell therapy | BCMA / CD19 | not yet graded | No reviewed efficacy summary in this indication | |
| Remestemcel-L (Ryoncil) | Phase 1/2 | Cell therapy | Allogeneic MSC therapy | not yet graded | No reviewed efficacy summary in this indication | |
| BDHK-2009 | Phase 1 | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| ExoFlo | Phase 1 | Cell therapy | MSC-derived exosomes | Weak signal | No reviewed efficacy summary in this indication | |
| Idrebormilast | Discontinued | Small molecule | PDE4 | Partial signal(overall) | No reviewed efficacy summary in this indication |
Large race: only the 79 furthest-along competitors are listed; 45 more exist in this indication but aren't shown. Use the search box to compare against any of them.
Compare side by side
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow PALI-2108 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
October 2027 (1)
Company guidance: data expected fourth quarter of 2027 (Palisade Bio, 10 Nov 2026). “Primary efficacy results for ASCENTRA-UC are expected in the fourth quarter of 2027.” Source ↗
Company guidance: topline data expected Q4 2027 (Palisade Bio, 10 Nov 2026). “First Patient Dosed in Global Phase 2b ASCENTRA-UC Trial; Topline Results Expected in Q4 2027” Source ↗
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent